Megan K. Yee

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction

C. Michael Gibson, Serge Korjian, Pierluigi Tricoci et al. · Circulation · 2016 · 186 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

C. Michael Gibson, Duane S. Pinto, Gerald Chi et al. · Circulation · 2016 · 95 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

GASTRIC EMPTYING AND SMALL BOWEL TRANSIT IN MALE VOLUNTEERS AFTER I.M. KETOROLAC AND MORPHINE

Megan K. Yee, W. D. Evans, P. Facey et al. · British Journal of Anaesthesia · 1991 · 93 citations · Full text

Medicine, Clinical Sciences, Pharmacokinetics +8

Ambient Fine Particulate Matter, Nitrogen Dioxide, and Term Birth Weight in New York, New York

David A. Savitz, Jennifer F. Bobb, Jillian Carr et al. · American Journal of Epidemiology · 2013 · 89 citations · Full text

Public Health, Environmental Sciences, Population Health Sciences +17

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

C. Michael Gibson, John J.P. Kastelein, Adam Phillips et al. · American Heart Journal · 2020 · 85 citations · Full text

Medicine, Cardiology, Pharmacology +17